This publication is presented to you through Paradigm Publishing Services
Stanford University Press
Chapter
Licensed
Unlicensed
Requires Authentication
13. Using Corporate Ethics Advice
You are currently not able to access this content.
You are currently not able to access this content.
Chapters in this book
- Frontmatter i
- Contents vii
- Acknowledgments xi
- Preface xv
-
Part I. Introduction
- Introduction 1
-
Part II. Ethics and Industry Overview
- 2. Ethics and Business Activity 21
- 3. Ethics Analysis Applied to Monsanto and the Labeling of rbST 70
- 4. Research Ethics 106
- 5. Industry Regulation and the Product Approval Process 129
-
Part III. Case Studies
- Research Collaborations Between Academia and Industry 149
- 7. Industry-Sponsored Clinical Research and the Use of Placebo Controls 195
- 8. Mitigation of Harm to Subjects Injured in Clinical Research 235
- 9. Conducting Clinical Research in Developing Countries 276
- 10. Anticipating and Managing Postmarket Problems 329
- 11. Access to Medical Products 377
- 12. Advertising Prescription Drugs Directly to Patients 427
- 13. Using Corporate Ethics Advice 480
- Index 519
Chapters in this book
- Frontmatter i
- Contents vii
- Acknowledgments xi
- Preface xv
-
Part I. Introduction
- Introduction 1
-
Part II. Ethics and Industry Overview
- 2. Ethics and Business Activity 21
- 3. Ethics Analysis Applied to Monsanto and the Labeling of rbST 70
- 4. Research Ethics 106
- 5. Industry Regulation and the Product Approval Process 129
-
Part III. Case Studies
- Research Collaborations Between Academia and Industry 149
- 7. Industry-Sponsored Clinical Research and the Use of Placebo Controls 195
- 8. Mitigation of Harm to Subjects Injured in Clinical Research 235
- 9. Conducting Clinical Research in Developing Countries 276
- 10. Anticipating and Managing Postmarket Problems 329
- 11. Access to Medical Products 377
- 12. Advertising Prescription Drugs Directly to Patients 427
- 13. Using Corporate Ethics Advice 480
- Index 519